Cargando…

Punicalagin Ameliorates Lupus Nephritis via Inhibition of PAR2

Lupus nephritis (LN) is the most frequent phenotype in patients with systemic lupus erythematosus (SLE) and has a high rate of progression to end-stage renal disease, in spite of intensive treatment and maintenance therapies. Recent evidence suggests that protease-activated receptor-2 (PAR2) is a th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seo, Yohan, Mun, Chin Hee, Park, So-Hyeon, Jeon, Dongkyu, Kim, Su Jeong, Yoon, Taejun, Ko, Eunhee, Jo, Sungwoo, Park, Yong-Beom, Namkung, Wan, Lee, Sang-Won
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7404282/ https://www.ncbi.nlm.nih.gov/pubmed/32674502 http://dx.doi.org/10.3390/ijms21144975

Ejemplares similares

Cinobufagin Exerts Anticancer Activity in Oral Squamous Cell Carcinoma Cells through Downregulation of ANO1
por: Jo, Sungwoo, et al.
Publicado: (2021)

GB83, an Agonist of PAR2 with a Unique Mechanism of Action Distinct from Trypsin and PAR2-AP
por: Heo, Yunkyung, et al.
Publicado: (2022)

VI-116, A Novel Potent Inhibitor of VRAC with Minimal Effect on ANO1
por: Jeon, Dongkyu, et al.
Publicado: (2022)

Non-histologic factors discriminating proliferative lupus nephritis from membranous lupus nephritis
por: Kwon, Oh Chan, et al.
Publicado: (2020)

Worse Renal Presentation and Prognosis in Initial-Onset Lupus Nephritis than Early-Onset Lupus Nephritis
por: Kwon, Oh Chan, et al.
Publicado: (2020)

Inhibition of ANO1 by Cis- and Trans-Resveratrol and Their Anticancer Activity in Human Prostate Cancer PC-3 Cells
por: Jeon, Dongkyu, et al.
Publicado: (2023)

Ani9, A Novel Potent Small-Molecule ANO1 Inhibitor with Negligible Effect on ANO2
por: Seo, Yohan, et al.
Publicado: (2016)

Inhibition of ANO1 by luteolin and its cytotoxicity in human prostate cancer PC-3 cells
por: Seo, Yohan, et al.
Publicado: (2017)

Glycol chitosan-based tacrolimus-loaded nanomicelle therapy ameliorates lupus nephritis
por: Kim, Chang Seong, et al.
Publicado: (2021)

ALW peptide ameliorates lupus nephritis in MRL/lpr mice
por: Wang, Huixia, et al.
Publicado: (2019)

Novel ANO1 Inhibitor from Mallotus apelta Extract Exerts Anticancer Activity through Downregulation of ANO1
por: Seo, Yohan, et al.
Publicado: (2020)

Physiological and Immune Functions of Punicalagin
por: Venusova, Eva, et al.
Publicado: (2021)

Mannose-Binding Lectin Blunts Macrophage Polarization and Ameliorates Lupus Nephritis
por: Cai, Yanxing, et al.
Publicado: (2013)

Repeated administration of alpha-galactosylceramide ameliorates experimental lupus nephritis in mice
por: Uchida, Takahiro, et al.
Publicado: (2018)

Novel CFTR Activator Cact-3 Ameliorates Ocular Surface Dysfunctions in Scopolamine-Induced Dry Eye Mice
por: Jeon, Dongkyu, et al.
Publicado: (2022)

Punicalagin Targets Atherosclerosis: Gene Expression Profiling of THP-1 Macrophages Treated with Punicalagin and Molecular Docking
por: Huwait, Etimad, et al.
Publicado: (2022)

ADSC secretome constrains NK cell activity by attenuating IL-2-mediated JAK-STAT and AKT signaling pathway via upregulation of CIS and DUSP4
por: Ko, Eunhee, et al.
Publicado: (2023)

The new complement inhibitor CRIg/FH ameliorates lupus nephritis in lupus-prone MRL/lpr mice
por: Shi, Yu, et al.
Publicado: (2019)

Potentiation of ΔF508- and G551D-CFTR-Mediated Cl(-) Current by Novel Hydroxypyrazolines
por: Park, Jinhong, et al.
Publicado: (2016)

Approach to Pregnancy in Patients With Lupus Nephritis
por: Tan, Benjamin, et al.
Publicado: (2023)

An Antinuclear Antibody-Negative Patient With Lupus Nephritis
por: Kim, Hyoun-Ah, et al.
Publicado: (2009)

suPAR and WT1 modify the adhesion of podocytes and are related to proteinuria in class IV lupus nephritis
por: Bollain-y-Goytia, Juan-José, et al.
Publicado: (2023)

The Pathogenesis of Lupus Nephritis
por: Sterner, Rosalie M., et al.
Publicado: (2014)

Pediatric lupus nephritis
por: Pinheiro, Sergio Veloso Brant, et al.
Publicado: (2018)

Hyperhomocysteinemia and Lupus Nephritis
por: Timlin, Homa, et al.
Publicado: (2019)

Management of Lupus Nephritis
por: Tamirou, Farah, et al.
Publicado: (2021)

Lupus Nephritis and Dysbiosis
por: Monticolo, Marta, et al.
Publicado: (2023)

Punicalagin, an active component in pomegranate, ameliorates cardiac mitochondrial impairment in obese rats via AMPK activation
por: Cao, Ke, et al.
Publicado: (2015)

Comparison of clinical features and outcomes between patients with early and delayed lupus nephritis
por: Ahn, Sung Soo, et al.
Publicado: (2020)

Involvement of Gut Microbiota in SLE and Lupus Nephritis
por: Mohd, Rozita, et al.
Publicado: (2023)

Laparoscopic biopsy-proven lupus nephritis in autosomal dominant polycystic kidney disease
por: Park, Ji In, et al.
Publicado: (2012)

Clinical and Genetic Risk Factors Associated With the Presence of Lupus Nephritis
por: Shin, Jung-Min, et al.
Publicado: (2021)

Kidney disease in lupus is not always 'lupus nephritis'
por: Anders, Hans-Joachim, et al.
Publicado: (2013)

Comparison of the Clinical Implications among Five Different Nutritional Indices in Patients with Lupus Nephritis
por: Ahn, Sung Soo, et al.
Publicado: (2019)

Lupus nephritis: current update
por: Saxena, Ramesh, et al.
Publicado: (2011)

The Role of Cytokine in the Lupus Nephritis
por: Iwata, Yasunori, et al.
Publicado: (2011)

Chapter 12: Lupus nephritis
Publicado: (2012)

Biomarker Profiling for Lupus Nephritis
por: Li, Yajuan, et al.
Publicado: (2013)

The Role of Autophagy in Lupus Nephritis
por: Wang, Linlin, et al.
Publicado: (2015)

Current status of lupus nephritis
por: Jaryal, Ajay, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_7fit0kmtvhgd5p5q02jn5fo3j8